Alto Neuroscience Inc

Earnings data Q1 2024

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Los Altos, CA.

LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress. “Our team's commitment to developing personalized therapies for the brain is exemplified by our continued clinical execution and the recent progress across our pipeline,” said Amit Etkin, M.D., Ph.D., founder and CEO of Alto Neuroscience. “We are proud to have initiated five Phase 2 clinical stud.

Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights

LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced upcoming data presentations that highlight the company's precision psychiatry pipeline and biomarker-based analyses at the Society of Biological Psychiatry (SOBP) and American Society of Clinical Psychopharmacology (ASCP) Annual Meetings, to take place May 9-11 in Austin, TX, and May 28-31 in Miami Beach, FL, respectively. “The vast amount of clinical and biomarker data we've generated to date enab.

Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences

LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced positive results from its healthy volunteer Phase 1 study of ALTO-101, a novel PDE4 inhibitor in development for cognitive impairment associated with schizophrenia (CIAS). Results from the study demonstrated favorable tolerability and improved pharmacokinetics of ALTO-101 when administered via a transdermal delivery system (TDS) compared to oral administration. The TDS formulation is being develope.

Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia

Alto Neuroscience (ANRO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Alto Neuroscience (ANRO): Strong Industry, Solid Earnings Estimate Revisions

LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the initiation of its Phase 2 double-blind, single- and multiple-dose study to determine the pharmacodynamic effects of ALTO-203 in MDD patients as well as assess its safety, tolerability, and pharmacokinetics. To date, ALTO-203 has demonstrated positive emotional and cognitive effects in healthy participants after a single dose. The present study will evaluate these effects in patients with MDD to.

Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder

LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the full year ended December 31, 2023, and highlighted recent corporate progress. “2024 is shaping up to be a transformational year for Alto as we advance our mission of redefining the treatment paradigm for patients with neuropsychiatric disorders,” said Amit Etkin, M.D., Ph.D., founder and CEO of Alto Neuroscience. “Our lead product candidates, ALTO-100 and ALTO-300, have dem.

Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights

Results from phase 2b study, using ALTO-100 for the treatment of patients with Major Depressive Disorder, expected in the 2nd half of 2024. Results from phase 2b study, using ALTO-300 for the treatment of patients with Major Depressive Disorder, expected in the 1st half of 2025. The major depressive disorder market across the 8 major markets is expected to grow to $9.6 billion in 2029.

Alto Neuroscience: Potential First-In-Class Approach To Targeting CNS Disorders

LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the appointment of Maha Radhakrishnan, M.D. to the company's board of directors. Dr. Radhakrishnan is an accomplished industry executive with decades of experience advancing large strategic portfolios across different therapeutic areas through product development and commercialization and overseeing the global medical strategy and operations within major biotechnology and pharmaceutical companies.

Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors

LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that company management will participate in the following upcoming investor conferences: Jefferies Biotech on the Bay Summit, March 12-13th: Alto management will participate in one-on-one meetings with investors during the conference. UBS Virtual CNS Day, March 18th: Amit Etkin, M.D., Ph.D., founder and chief executive officer, will participate in a fireside chat on Monday, March 18, 2024, at 2:30.

Alto Neuroscience to Participate in Upcoming Investor Conferences

LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Amit Etkin, M.D., Ph.D., founder and chief executive officer, will present a company overview at the TD Cowen 44th Annual Healthcare Conference on Tuesday, March 5, 2024, at 1:30 pm ET. The presentation will also be available via live webcast on the Events and Presentations page in the Investors section of Alto's website and a replay will be available for 90 days following the presentation. Ab.

Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference

LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the closing of its previously announced upsized initial public offering of 9,246,000 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 1,206,000 additional shares, at a public offering price of $16.00 per share. The aggregate gross proceeds to Alto from the offering were approximately $147.9 million before deducting underwriting discounts an.

Alto Neuroscience Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Amer Sports Inc

American Healthcare REIT Inc

Fibrobiologics Inc

Flutter Entertainment PLC

Fractyl Health Inc

Kyverna Therapeutics Inc

Perfect Moment Ltd

BBB Foods Inc

Sports equipment and apparel maker Amer Sports priced below the range to raise $1.3 billion at a $6.4 billion market cap. CNS disorder biotech Alto Neuroscience priced its upsized IPO at the top of the range to raise $129 million at a $456 million market cap.

U.S. IPO Weekly Recap: Amer Sports' Billion-Dollar U.S. IPO Leads A Week Of Large Listings

LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the pricing of its upsized initial public offering of 8,040,000 shares of common stock at a public offering price of $16.00 per share. The aggregate gross proceeds to Alto from the offering are expected to be approximately $128.6 million before deducting underwriting discounts and commissions and other offering expenses payable by Alto. In addition, Alto has granted the underwriters a 30-day option.

Alto Neuroscience Announces Pricing of Upsized Initial Public Offering

Alto Neuroscience announced that it has filed for a proposed initial public offering (IPO) to raise up to $100 million.   It plans to list on the NYSE under the symbol ‘ANRO', but no pricing terms were disclosed.

Alto Neuroscience files for IPO to raise up to $100M

Alto Neuroscience, Inc. has filed for a $100 million IPO to develop treatments for brain and central nervous system conditions, although the final figure may differ. The company's lead candidate, ALTO-100, is in Phase 2 trials for major depressive disorder and post-traumatic stress disorder. The global market for depression treatment is expected to reach $16.8 billion by 2032, with the treatment for PTSD also a large market, driving demand for Alto's drug candidates.

Alto Neuroscience Starts IPO Plan For CNS Disorder Treatments

News for Alto Neuroscience Inc Stock (ANRO)